NeoGenomics NEO Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| NET REVENUE by Product | ||||||
| Client direct billing | $131.61M+7.8% | $133.36M+8.2% | $132.29M+8.7% | $131.16M+10.9% | $122.04M+8.8% | |
| Commercial insurance | $30.94M+24.5% | $31.42M+17.5% | $32.47M+31.6% | $28.77M+15.8% | $24.86M+5.3% | |
| Medicare and other government | $24.15M+14.4% | $25.4M+16.8% | $22.97M+7.9% | $21.39M+0.9% | $21.1M+3.6% | |
| Self-pay | -$17K-144% | —— | $69K-68.3% | $20K-87.3% | $39K-50.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does NeoGenomics break its business down?
- NeoGenomics (NEO) reports net revenue by product across 4 parts — Client direct billing, Commercial insurance, Medicare and other government and Self-pay. Each is extracted from the segment footnotes and tracked over time.
- Where does NeoGenomics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in NeoGenomics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
